Newscast – Page 84 – media

ResearchKit Study to Test Smartphones’ mHealth Value in Eye Studies

Novartis is launching an mHealth app on Apple's ResearchKit platform to determine whether smartphones are reliable enough for use in ophthalmology studies.
- Source: mHealth Intelligence
- 661
- April 26, 2018
mHealth Researches
Urotronic gets OK for advanced trial to treat narrowed urethras

Plymouth-based medical device maker Urotronic is ramping up clinical research on its Optilume drug-coated balloon to treat men with narrowed urethras, accelerating the data-gathering process for its novel device.
- Source: StarTribune
- 1,926
- April 26, 2018
FDA medical device medtech Researches
Takeda reaches preliminary deal to buy Shire for close to $65B

Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
- Source: endpts
- 675
- April 25, 2018
Lexington Market Views Shire Takeda
Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies

- A CD19 CAR with novel targeting properties designed to reduce cytokine release syndrome –
- Source: autolus
- 593
- April 25, 2018
B-cell malignancies Market Views T-cell therapies
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
- Source: prnewswire
- 691
- April 25, 2018
baricitinib Eli Lilly New Approvals RA
UCB snags an NDA-ready epilepsy drug from Proximagen in $370M deal

UCB is beefing up its pipeline of epilepsy drugs with an NDA-ready therapy from Proximagen. The Belgian company has agreed to buy their nasal spray therapy USL261, designed as a rescue therapy for acute repetitive seizures, for $150 million in cash and another $220 million in sales and regulatory milestones.
- Source: endpts
- 587
- April 25, 2018
acute repetitive seizures Market Views Proximagen UCB
‘Orangeworm’ hacking campaign hits X-ray and MRI machines

Malware from a newly disclosed hacking campaign has infected the networks of multinational health care companies, including some X-ray and MRI machines, cybersecurity firm Symantec warned Monday.
- Source: CyberScoop
- 745
- April 25, 2018
cybersecurity Market Views
New partnership announced to prepare Australian GPs for the national expansion of My Health Record

GPs will be actively involved in the delivery of the Federal Government’s My Health Record, with a new partnership designed to train doctors in the use of the national online health information repository and prepare them to answer patients’ questions.
- Source: Healthcare IT
- 563
- April 25, 2018
healthcare Market Views
UCSD launching pilot trial of glucose-sensing ‘tattoo’

Researchers from the University of California San Diego have developed a low-cost, single-use tattoo-like wearable that measures the user’s glucose levels. According to a release from the institution, this noninvasive technology will be at the center of a newly announced pilot clinical trial designed to test the accuracy and acceptability of the tattoos.
- Source: MobiHealthNews
- 610
- April 25, 2018
blood glucose Researches
Inventiva Raises €35.5 Million Through A Capital Increase With European And US Investors

Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announces the successful completion of the issuance of 5,572,500 new ordinary shares without preferential subscription rights (the "New Shares") for a total gross proceeds of approximately €35.5 million by means of a private placement reserved to a specified category of investors as described below (the "Reserved Offering"). The Reserved Offering was conducted by Jefferies International Limited, acting as Global Coordinator and Joint Bookrunner, and Société Générale Corporate & Investment Banking and Gilbert Dupont acting as Joint Bookrunners (together with the Global Coordinator and Joint Bookrunner, the "Managers"). Namsen Capital acted as Inventiva's Capital Markets Advisor.
- Source: drugdu
- 617
- April 24, 2018
Market Views MPS NASH Series SSc

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.